Bioequivalence of Apixaba

Not Applicable

• Conditions: Determination of plasma concentration of Apixaban 5 mg pharmaceutical product.; Anticoagulant antagonists, vitamin K and other coagulants; Y44.3

• Registration Number: IRCT20210201050197N4
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Healthy volunteer
Age: 18-50 year

Exclusion Criteria

History of liver, kidney and cardiovascular diseases that can affect drug clearance from body
History of taking any medication in the last two weeks
Creatinine above 2

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maximum plasma concentration of the drug. Timepoint: Before intervention and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 32, 48 hours after intervention. Method of measurement: liquid chromatography-mass (LC-MS) device.